Literature DB >> 9564628

Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.

J P Finberg1, J Wang, K Bankiewicz, J Harvey-White, I J Kopin, D S Goldstein.   

Abstract

Striatal extracellular fluid concentrations of dopamine and metabolites in response to direct striatal administration of two L-DOPA boluses administered sequentially were determined in three rhesus monkeys during halothane anesthesia. Whereas in an initial microdialysis run, generation of dopamine was less following the second L-DOPA bolus than the first, in a subsequent run, in which the selective MAO-B inhibitor R(+)-N-propargyl-1-aminoindan (rasagiline) was administered systemically (0.2 mg/kg s.c.) between the two L-DOPA boluses, generation of dopamine was greater following the second bolus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564628     DOI: 10.1007/978-3-7091-6499-0_28

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  23 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 4.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 5.  Rasagiline.

Authors:  M Asif A Siddiqui; Greg L Plosker
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.

Authors:  Eduardo L G Moreira; Daniel Rial; Aderbal S Aguiar; Cláudia P Figueiredo; Jarbas M Siqueira; Silvia DalBó; Heros Horst; Jade de Oliveira; Gianni Mancini; Tiago S dos Santos; Jardel G Villarinho; Francielle V Pinheiro; José Marino-Neto; Juliano Ferreira; Andreza F De Bem; Alexandra Latini; Moacir G Pizzolatti; Rosa M Ribeiro-do-Valle; Rui D S Prediger
Journal:  J Neural Transm (Vienna)       Date:  2010-10-08       Impact factor: 3.575

7.  Spotlight on rasagiline in Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Inhibition of monoamine oxidase by (E)-styrylisatin analogues.

Authors:  Elizna M Van der Walt; Erika M Milczek; Sarel F Malan; Dale E Edmondson; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Journal:  Bioorg Med Chem Lett       Date:  2009-03-14       Impact factor: 2.823

Review 9.  Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Authors:  Jack J Chen; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Rasagiline: a review of its use in the management of Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.